Enbio

At a glance

Enbio filed 63 disclosures in the last 12 months, including 28 insider, 1 contract, 1 5% holder and 1 issuance. The most recent key filing was on Oct 22: CEO bought 2,006 sh on the market at an average ₩1,953, Aug 11–Oct 22.

Revenue for 2025 was ₩34B, down 4.8% on 2024. Operating margin was 2.7% against 3.9% a year earlier. Debt was 63% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩24.6B and operating profit of ₩3.3B.

The 2025 annual report lists 158 employees with an average tenure of 4.9 years and average pay of ₩44.2M, #1977 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩129.1M each on average. It paid no cash dividend for 2025. 이명재 and related parties held 31.41% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 6.22% on Oct 13.

From the 2025 annual report

Staff: 158 (119 men, 39 women), of whom 47 on fixed-term contracts. Total pay for the year: ₩7B. Directors and auditors: 8, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

이명재 holds 29.61%; with 7 related parties the group holds 31.41% of common shares at year end (from 30.57% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 26% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports